<unk>  is a HMG-CoA reductase inhibitor that is FDA approved for the treatment of primary hyperlipidemia and mixed dyslipidemia.   Common adverse reactions include rhabdomyolysis with myoglobinuria, acute renal failure, myopathy (including myositis) and liver enzyme abnormalities.
Pitavastatin
Enoxaparin
Iotalamic acid
Ticlopidine
Abciximab
Apixaban
Picloxydine
Heparin